✦ LIBER ✦

176 NUMBER NEEDED TO TREAT AND RISK BENEFIT ANALYSIS OF DENOSUMAB VERSUS ZOLEDRONIC ACID IN THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER PATIENTS WITH BONE METASTASES

✍ Scribed by Xie, Jipan; Diener, Melissa; Wu, Eric; Sorg, Rachael; Yu, Andrew; Namjoshi, Madhav

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Denosumab versus zoledronic acid for tre

✍ Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawr 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 840 KB

Re: Denosumab Versus Zoledronic Acid for

✍ Walsh, Patrick C. 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 110 KB

P347 Benefit of denosumab therapy in pat

✍ M. Martin; G. Steger; R. von Moos; A. Stopeck; R. de Boer; H. Bourgeois; K. Inou 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 35 KB

3602 POSTER The Number Needed to Treat (

✍ G. Dranitsaris; S. Kaura 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 39 KB

AOSOP6 Results from the 2-year open-labe

✍ A.T. Stopeck; A. Lipton; M. Martín; J-J. Body; A. Paterson; G.G. Steger; K. Tonk 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB